Results 111 to 120 of about 11,703 (213)
Progress in RNA‐Targeted Therapeutics for Human Diseases
MedComm, Volume 7, Issue 2, February 2026.RNA‐targeted therapies are revolutionizing molecular medicine by transitioning from a “protein‐centric” focus to an “RNA‐regulatory network” approach. Leveraging RNA's diverse roles in gene regulation, signaling, and epigenetic modifications, advanced platforms such as ASOs, siRNA, miRNA, mRNA, aptamers, shRNA, and CRISPR/Cas systems are enabling ...
Wangzheqi Zhang +10 more
wiley +1 more source
Targeting oncogenic fusion-driven NUT carcinoma with CRISPR-Cas9 genome editing
Molecular Therapy: OncologyNUT carcinoma (NC) is a highly aggressive malignancy characterized by an oncogenic fusion gene incorporating the NUTM1 gene. To date, no established treatment options exist.
Maxim F. Carle +7 more
doaj +1 more source
Molecular Therapy: OncologyNUT carcinoma (NC) is a rare, yet aggressive disease (median survival of 6.5 months) of the young defined by a translocation of the nuclear protein in testis gene 1 (NUTM1).
Rieka C. Buchenau +13 more
doaj +1 more source
Stem Cells International, 2017 Antitumor efficacy of systemically administered oncolytic adenoviruses (OAdv) is limited due to diverse factors such as liver sequestration, neutralizing interactions in blood, elimination by the immune system, and physical barriers in tumors.
R. Moreno +6 more
doaj +1 more source
IgE‐Sensitized Mast Cells: A Programmable Platform for Antigen‐Triggered Oncolytic Virotherapy
MedComm – Future Medicine, Volume 5, Issue 1, March 2026.
Lin Chen, Yu‐Xuan Jin, Jin‐Lyu Sun
wiley +1 more source
OncoImmunology, 2019 Antitumor cytotoxic T lymphocytes (CTLs) are essential for immune surveillance, yet the blockade of eliciting such CTLs during oncolytic virotherapy remains incompletely understood.
Zhiwu Tan +9 more
doaj +1 more source
Release the hounds: virotherapy with immunotherapy [PDF]
Blood, 2016 In this issue of Blood, Shen et al demonstrate that the vesicular stomatitis virus (VSV)-murine interferon β (IFNβ)-sodium iodide symporter (NIS) (VSV-mIFNβ-NIS) oncolytic virus has significant antileukemia activity, which is enhanced when combined with an anti-programmed death-ligand 1 (PD-L1) antibody.
openaire +2 more sources
Patient-derived tumoroids and proteomic signatures: tools for early drug discovery
Frontiers in ImmunologyOnco-virotherapy is an emergent treatment for cancer based on viral vectors. The therapeutic activity is based on two different mechanisms including tumor-specific oncolysis and immunostimulatory properties.
Hélène Lê +11 more
doaj +1 more source
Editorial: Oncolytic virotherapy
Frontiers in Molecular Biosciences, 2023 Ahmed Majeed Al-Shammari +2 more
openaire +3 more sources